TRIO-012: A multicenter, multinational, randomized, double-blind phase iii study of imc-1121b plus docetaxel versus placebo plus docetaxel in previously untreated patients with her2-negative, unresectable, locally recurrent or metastatic breast cancer

1. MacKey, J.
2. Gelmon, K.
3. Martin, M.
4. McCarthy, N.
5. Pinter, T.
6. Rupin, M.
7. Youssoufian, H.